NeuroTech Analytics releases industry-first report

New open-access analytical report profiles top technologies, sectors, trends, companies, investors, R&D hubs and influencers in the Global NeuroTech Industry

“Global NeuroTech Industry Landscape Overview 2020” is the inaugural report of NeuroTech Analytics, a new source of NeuroTech industry analytics; the report delivers market mapping and landscape analysis to identify the key players in NeuroTech, to understand the broad context in which they are operating, and how they are deploying their technology strategy.

NeuroTech Industry 2020 Landscape Overview
NeuroTech Industry 2020 Landscape Overview

“With the publication of this comprehensive analytical report on the global NeuroTech Industry, we bring NeuroTech.com deeper into the realm of quantitative and tangible industry analysis, benchmarking and forecasting within the rapidly-developing and diversifying NeuroTech sector,” said Alon Braun, Co-Founder of NeuroTech Analytics.

Last year we spoke with Bruce Yankner, professor of genetics at Harvard Medical School and co-director of the Paul F Glenn Center for the Biology of Aging, to explore neural tech and the role it can play in Longevity, he told us: “The idea that neural circuit activity in the brain can have far-reaching effects on lifespan is exciting, and raises the possibility of a previously unanticipated mode of regulation of the aging process.”

The analytics behind the report enable the identification of critical trends, technologies and approaches shaping the sector, and pinpoints the domains that are well served by existing players, as well as underrepresented areas lacking a critical mass of industry development. The market is definitely hotting-up.

“NeuroTech has enormous potential to disrupt a number of different industries and aspects of the human condition, from overcoming disability to enhancing cognitive performance, sleep, meditation, preventive health, Longevity and more. It is a rapidly developing frontier-technology driven sector complexified by its use of technologies like Artificial Intelligence, mathematics and data science that are evolving at breakneck speed,” said Dmitry Kaminskiy, Co-Founder of NeuroTech Analytics.

The Global Neurotech Industry is one of the most promising and prospective sectors of technology: annual growth of investment in neurotechnology is 31% while the average growth for life science investment, in general, is 12%.

Private capital funds invested more than $19 billion in NeuroTech companies since the year 2000. Corporations, investors and other counterparties who succeed to tap into the current wave of industry growth and development will gain essential competitive advantages in their struggle for new markets, audiences, funding and technologies.

Some NeuroTech subsectors are already well-established and mature, with practical implementations and products either already on the market or set to appear in the next several years, whereas other subsectors are still emerging, and dominated by early-stage startups.

Neurotech.com is the creation of Alon Braun from Riverbanks Solutions and Dmitry Kaminskiy from Deep Knowledge Group.

Image credit: Nathan R from Pixabay

Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Biomarkers for aging – a consensus is needed now more than ever

Slowing, stopping and even reversing aging – how can we research progress if we can't measure success? Biomarkers of aging are pretty important in the...

Hereafter: conversations in the afterlife

We speak to Dadbot creator James Vlahos about using conversational AI to better remember loved ones who have passed away; a very interesting step...

VR and AI used to generate structures to attack Coronavirus

Virtual reality and artificial intelligence come together to generate new chemicals from scratch which could be used against SARS-CoV-2. A new paper has outlined...

Exclusive video interview: Human Longevity Inc.’s Chairman

After $0.5bn cumulative investment, Human Longevity Inc. pivots into high-end medical services to seek scale and ROI. For a few years we tracked Human Longevity Inc.'s...